Terms: = Pancreatic cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Staging
3 results:
1. Volumetric Parameters Derived from cxcr4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas.
Michalski K; Schlötelburg W; Hartrampf P; Heinrich M; Serfling S; Buck AK; Werner RA; Kosmala A; Weich A
Mol Imaging Biol; 2024 Apr; 26(2):344-350. PubMed ID: 38332341
[TBL] [Abstract] [Full Text] [Related]
2. Impact of cxcr4-Directed PET/CT on staging and Proposed Oncologic Management in Patients With Digestive System Tumors.
Weich A; Serfling SE; Schlötelburg W; Higuchi T; Hartrampf PE; Schirbel A; Heinrich M; Buck AK; Rowe SP; Kosmala A; Werner RA
Clin Nucl Med; 2023 Jul; 48(7):586-593. PubMed ID: 37167408
[TBL] [Abstract] [Full Text] [Related]
3. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract] [Full Text] [Related]
